The global anatomic pathology market is expected to reach USD 21.9 Billion by 2021 from USD 16.2 Billion in 2016, at a CAGR of 6.1% from 2016 to 2021.
The increasing prevalence of chronic diseases, growing aging population, and increasing healthcare expenditure are the major factors driving the growth of this market.
Anatomic pathology involves the diagnosis of various types of cancer, infectious diseases, and medical conditions through the examination of cells and tissue samples, which are collected from patients through biopsy. The market is witnessing high growth due to factors such as increasing prevalence of chronic diseases, growing aging population, and increasing healthcare expenditure.
To know about the assumptions considered for the study, download the pdf brochure , here: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145
Anatomic Pathology Market segmentation:
- by Product & Service
- by Application
- by Region
The Major Players Operating in the Anatomic Pathology Market:
Key players operating in the market include F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Agilent Technologies (U.S.), Sakura Finetechnical Co., Ltd. (Japan), Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), and NeoGenomics Laboratories, Inc. (U.S.).
Geographical Detailed Analysis for Anatomic Pathology Market:
The anatomic pathology market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The growing prevalence of chronic diseases, rapidly increasing aging population, rising acceptance of personalized medicine, growing academic and government investments in diagnostic research, and the presence of a large number of major market players in this region are further driving the growth of this Anatomical pathology market.
Read More in Detailed (Anatomic Pathology Market):
